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Abstract 
Background: To analyze whether medical care is in accordance with guidelines for secondary prevention of myocar-
dial infarction (MI), or stroke in patients with type 2 diabetes from Germany and Austria.
Methods: 29,325 patients (≥20 years of age) with type 2 diabetes and MI, or stroke, documented between 2006 and 
2015 were selected from the Diabetes-Patienten-Verlaufsdokumentation database. We analyzed medication, clini-
cal characteristics, and lifestyle factors according to national secondary prevention guidelines in patients with MI, or 
stroke, separately.
Results: HbA1C <7.5 % was achieved in 64.9 % (MI), and in 61.1 % (stroke) of patients. LDL <100 mg/dl was docu-
mented in 56.2 % (MI), and in 42.2 % (stroke). Non-smoking was reported in 92.0 % (MI), and in 93.1 % (stroke), physical 
activity in 9.6 % (MI), and 5.5 % (stroke). Target values of blood pressure (<130/80 mmHg in MI, 120/70–140/90 in 
stroke) were reached in 67.0 % (MI), and in 89.9 % (stroke). Prescription prevalence of inhibitors of platelet aggrega-
tion (IPA) was 50.7 % (MI), and 31.7 % (stroke). 57.0 % (MI), and 40.1 % (stroke) used statins, 65.1 % (MI), and 65.8 % 
(stroke) used any type of antihypertensives, and ACE inhibitors were prescribed in 49.7 % (MI), and 41.3 % (stroke). A 
body mass index (BMI) <27 kg/m2 and the use of beta blockers were only recommended in subjects with MI. Of the 
patients with MI, 32.0 % had a BMI <27 kg/m2, and 59.5 % used beta blockers.
Conclusions: Achievement of treatment goals in secondary prevention of MI, or stroke in subjects with type 2 
diabetes needs improvement. Target goals were met more frequently in patients with MI compared to subjects with 
stroke. Especially the use of IPA was very low in patients with stroke. There remains great potential to reduce the risk of 
repeated macrovascular events and premature death, as well as to increase patients’ quality of life.
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Background
The prevalence of type 2 diabetes is increasing worldwide 
[1–3]. Moreover, studies indicate an earlier onset of type 
2 diabetes and a longer life-expectancy with diabetes [2, 
4]. A prolonged exposure to an adverse diabetic milieu 
and a high prevalence of cardiovascular risk factors (as 
obesity, hypertension, or dyslipidemia) [5], contribute to 
a high risk for macrovascular complications (MVCs) as 
myocardial infarction (MI), or stroke. In patients with 
diabetes, cardiovascular disease (CVD) is two to eight 
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folds higher compared to the general population and is 
the leading cause of death [6–8]. Additionally, disease 
progression in patients with type 2 diabetes seems to be 
more severe with a worse long-term prognosis compared 
to subjects without diabetes [5, 9]. MVCs have an adverse 
effect on patients’ quality of life and are also a huge public 
health problem due to high economic costs [10–12].
German and international guidelines (from e.g. the 
American Heart Association) for secondary prevention 
of MI and stroke aim to reduce cardiovascular morbid-
ity and mortality and to improve patient’s quality of life 
[8, 13–15]. These guidelines address pharmacological and 
lifestyle interventions, and provide target values amongst 
others for serum glucose, blood pressure, or serum lipids 
[8, 13–15]. However, data of previous studies indicate a 
suboptimal implementation of guidelines in medical care 
[16–21]. Although there are studies analyzing primary 
prevention of CVD risk factors in patients with diabetes 
[21–25], or adherence to secondary prevention guide-
lines in the general population [26–29] no studies exist 
investigating the achievement of current guideline targets 
for secondary prevention of MVCs in subjects with type 
2 diabetes.
Our objective was to examine whether medical care in 
patients with type 2 diabetes who already experienced a 
MI or stroke meets current guideline recommendations 
for secondary prevention. We also analyzed sociodemo-




Data were provided by the German/Austrian DPV (Dia-
betes-Patienten-Verlaufsdokumentation) registry. The 
DPV software is used for standardized, prospective docu-
mentation of diabetes care and outcome and is currently 
used by 428 centers from Germany (n = 398) and Austria 
(n = 30). Twice a year, data are anonymized and transmit-
ted from the participating health care facilities to Ulm, 
Germany, and aggregated into a cumulative database for 
clinical research and quality assurance [16]. Implausible 
and inconsistent data are reported back to the centers for 
verification or correction. The DPV initiative is approved 
by the Ethics Committee of the University of Ulm, Ger-
many and data collection by the local review boards.
As of March 2015, 404,609 patients were registered in 
DPV. Adult patients (≥20 years of age) with type 2 diabe-
tes documented during the year 2006 or thereafter were 
included; leaving 221,943 subjects from 178 participating 
centers (Fig. 1). If a macrovascular complication (stroke, 
or MI) was documented in the DPV software by the phy-
sician, the patient was assigned to the respective patient 
group (“MI only”, “stroke only”, “MI and stroke”). The 
diabetic foot syndrome (DFS) is a result of macrovascular 
and polyneuropathic complications. Additionally, guide-
lines for DFS contain recommendations primarily for 
wound management [30]. Hence, patients with DFS were 
excluded from the present analysis (n = 19,784; Fig. 1).
Due to heterogeneity on medical possibilities, and 
available drugs, data before the year 2006 were excluded. 
The recommendations considered did not differ between 
the year 2006 and 2015. For each patient, the last year of 
treatment was analyzed.
Outcomes
Sociodemographic characteristics (as e.g. sex, age, and 
age at diagnosis), clinical data (HbA1C, BMI, serum lipids, 
systolic and diastolic blood pressure), and lifestyle fac-
tors (smoking, physical activity) were compared between 
patients with at least one MVC (MI, stroke, or both) or 
patients without MVCs.
We considered variables according to national guide-
lines. In patients with MI, we analyzed HbA1C (<7.5 %), 
blood pressure (<130/80  mmHg), LDL-cholesterol 
(<100 mg/dl), body mass index (BMI) (<27 kg/m2), medi-
cal treatment (inhibitors of platelet aggregation (IPA), 
statins, beta blockers, ACE inhibitors, and any type of 
antihypertensives), smoking (yes/no), and physical activ-
ity (yes/no) [13].
In patients with stroke, we analyzed HbA1C (<7.5  %), 
blood pressure (systolic 120–<140  mmHg/diastolic 
70–<90 mmHg), LDL-cholesterol (<100 mg/dl), medical 
treatment (IPA, statins, ACE inhibitors, and any type of 
antihypertensives), smoking (yes/no), and physical activ-
ity (yes/no) [14, 15].
HbA1C was mathematically standardized to the refer-
ence range of 20–42  mmol/mol (diabetes control and 
complication trial: 4.05–6.05  %) by applying the multi-
ple-of-the-mean transformation method [31]. Systolic 
and diastolic blood pressure as well as serum lipids were 
measured in local laboratories compliant with national 
guidelines [32]. Information on smoking behavior and 
physical activity in supervised sports groups were based 
on patient self-reports to their diabetes-care teams.
Statistical analysis
Sociodemographic characteristics and clinical data were 
presented as median (Q1;Q3), or as percentage. To com-
pare groups, Chi square (χ2) test was used for dichoto-
mous variables, and Kruskal–Wallis test for continuous 
variables. The false discovery rate (FDR) was applied 
to correct p-values for multiple comparisons [33]. To 
analyze potential gender-differences in drug use, clini-
cal characteristics, and recommended lifestyle, logistic 
regression models were applied in “MI only” and “stroke 
only” groups. Due to differences in age distribution 
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among men and women, data were adjusted for age-
groups (20–<65, 65–<75, >75 years of age).
Due to the large number of subjects studied, a two-
sided p value <0.01 was considered significant. All statis-
tical analyses were implemented with SAS 9.4 (Statistical 
Analysis Software, SAS Institute, Cary, NC, USA).
Results
Differences between patients with or without MVCs
We included a total of 202,159 type 2 diabetes sub-
jects (male: 51.4  %) with a median age of 70.6 (Q1;Q3: 
60.6;77.9) years and a median diabetes duration of 8.1 
(2.7;14.1) years. Of the patients included, 29,325 had at 
least one MVC. In subjects with MVCs, there was a male 
preponderance (57.6 vs. 50.3 %; p < 0.0001), their median 
age was higher (73.6 vs. 69.9  years; p  <  0.0001) and the 
diabetes duration was longer (9.8 vs. 7.8 years; p < 0.0001) 
compared to patients without MVCs (Table 1). Total cho-
lesterol as well as LDL-cholesterol were higher in patients 
without MVCs (both p  <  0.0001). Differences between 
patient groups are described in detail in Table 1.
Differences within patients with MVCs
We also analyzed differences in sociodemographic and 
clinical characteristics between type 2 diabetes patients 
with MI only (n = 15,015), stroke only (n = 11,738), or 
both MVCs (MI and stroke) (n  =  2572) (Table  2). The 
lowest percentage of women was present in patients 
Fig. 1 Selection of study population
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with MI only (37.0  %), and the highest in patients with 
stroke only (49.9  %). Age at diabetes diagnosis was ear-
lier in patients with MI (60.9  years) compared to the 
other groups (e.g. 63.9 years in patients with stroke). Dia-
betes duration was longest in patients with both MVCs 
(11.0 years) (Table 2). Diastolic and systolic blood pres-
sure were higher in patients with stroke (135/80 mmHg) 
compared to patients with MI (130/74  mmHg) or both 
MVCs (130/75 mmHg). Total- and LDL-cholesterol were 
highest in patients with stroke. A comprehensive descrip-
tion of patient characteristics can be found in Table 2.
Achievement of target goals and medication in patients 
with type 2 diabetes and MI
Approximately two-thirds of the patients with type 2 dia-
betes and MI achieved target values of HbA1C (64.9  %) 
and blood pressure (67.0  %) (Fig.  2a). More than half of 
the patients (56.2 %) reached target value of LDL-choles-
terol. Guidelines also recommend weight loss in subjects 
with a BMI over 27 kg/m2. In our patients with MI, only 
one-third (32.2 %) had a BMI of less than 27 kg/m2. Physi-
cal activity was self-reported by 9.6  % and non-smoking 
by 92.0 % of the patients (Fig. 2a). Use of different phar-
maceutical agent classes as per recommendation was doc-
umented in 50 % (use of IPA) to 65 % (use of any type of 
antihypertensives) of patients (Fig. 2b). Of those patients 
treated with antihypertensives (n = 9773), 66.6 % reached 
target values of blood pressure. In subjects treated with 
statins (n = 8556), 62.8 % achieved LDL <100 mg/dl.
Achievement of target goals and medication in patients 
with type 2 diabetes and stroke
In most patients with stroke (89.9  %), target values of 
blood pressure were reached. Less than two-thirds had an 
HbA1C of <7.5 % (Fig. 3a). LDL-cholesterol under 100 mg/
dl was only documented in 42.2 %. 5.5 % of the patients 
reported to be physically active, 93.1 % were documented 
as non-smokers (Fig. 3a). About two-thirds of the patients 
were treated with any type of antihypertensive drugs, 
whereas the use of IPA, statins or ACE inhibitors was 
only documented in 30  % to 40  % of the subjects with 
stroke (Fig. 3b). In patients treated with antihypertensives 
(n = 7726), 89.3 % met a blood pressure between 120/70 
and 140/90  mmHg. 49.8  % of statin-treated patients 
(n = 4710) reached target value of LDL <100 mg/dl.
Gender differences in the attainment of guideline 
recommendations
Logistic regression analysis revealed a slightly, but sig-
nificantly better achievement of recommended treatment 
goals in men compared to women (Table 3). The biggest 
difference was observed in LDL-cholesterol. In subjects 
with MI, 60.1  % of men and 49.2  % of women reached 
the target value of <100  mg/dl (p  <  0.0001). In patients 
with stroke, 46.1 % of men and 38.3 % of women met the 
goal. Only the proportion of non-smokers was higher in 
women compared to men (MI: 94.0 vs. 92.0  %; stroke: 
95.3 vs. 92.4 %; both p < 0.0001). Table 3 summarizes all 
gender-differences.
Table 1 Comparison of  sociodemographic and  clinical characteristics between  type 2 diabetes patients with  and with-
out MVC
Data are medians (Q1;Q3) unless otherwise indicated
* p values adjusted for multiple comparisons by FDR
Patients with type 2 diabetes  
without macrovascular complication  
(MI, or stroke) (n = 172,834)
Patients with type 2 diabetes and at  
least one macrovascular complication  
(MI, or stroke) (n = 29,325)
p*
n n
Men,  % 172,834 50.3 29,325 57.6 <0.0001
Age (years) 172,834 69.9 (59.6;77.5) 29,325 73.6 (66.5;79.8) <0.0001
Age at diagnosis (years) 172,834 59.1 (49.2;68.6) 29,325 62.2 (52.7;70.5) <0.0001
Diabetes duration (years) 172,834 7.8 (2.6;13.8) 29,325 9.8 (4.2;16.0) <0.0001
BMI (kg/m2) 152,737 29.9 (26.3;34.5) 26,044 29.0 (25.8;32.9) <0.0001
HbA1C (%) 156,314 7.1 (6.2;8.4) 27,091 6.9 (6.2;8.2) <0.0001
Systolic BP (mmHg) 161,233 130.0 (120.0;144.0) 28,368 130.0 (120.0;140.0) <0.0001
Diastolic BP (mmHg) 161,073 80.0 (70.0;80.0) 28,345 75.0 (70.0;80.0) <0.0001
Total Chol (mg/dl) 122,629 187.0 (156.0;221.0) 23,645 171.0 (143.0;205.0) <0.0001
LDL-Chol (mg/dl) 109,060 111.0 (85.0;139.0) 22,328 99.0 (76.0;128.0) <0.0001
HDL-Chol (mg/dl) 111,496 43.0 (35.0;54.0) 22,389 42.0 (34.0;51.0) <0.0001
Physical inactivity,  % 59,410 90.0 11,293 92.5 <0.0001
Smoking, yes,  % 121,303 12.5 23,448 9.4 <0.0001
Cigarettes per day 15,173 14 (10;20) 2213 15 (10;20) 0.0975
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Discussion
Our aim was to analyze the adherence to guidelines for 
secondary prevention of MI or stroke in patients with type 
2 diabetes who already experienced a MI, or stroke. Over-
all, concordance with recommendations is rather mixed. 
Achievement of target values was best for glycaemic con-
trol and blood pressure. Almost all patients reported to 
be a non-smoker. Hardly anyone was physically active in 
supervised sport groups. Even use of medication accord-
ing to guidelines was quite poor, except for the use of 
antihypertensives. Treatment goals were met more often 
in subjects with MI compared to subjects with stroke. 
Particularly the use of IPA was very low in patients with 
stroke. We further investigated sociodemographic and 
clinical characteristics in patients with and without MVCs.
Differences between patients with or without MVCs
Our analysis revealed lower rates of CVD risk factors in 
patients with MVCs (Table 1). Especially blood lipids and 
diastolic blood pressure were lower in patients with MI, 
or stroke. One explanation for the differences found is 
that in our analysis, patients with MVCs more frequently 
receive lipid-lowering drugs (45.1 vs. 23.8  %) or antihy-
pertensives (65.8 vs. 48.7 %) compared to subjects with-
out MVCs. It can be also assumed that patients with a 
history of at least one MVC are more concerned about 
their health. Furthermore it is possible that medical 
care is more intensive in subjects with MVCs and physi-
cians might be more focused on CVD risk factors. This 
assumption can be supported by results of the German 
DETECT study, indicating that prescription rates of 
guideline recommended medication in subjects with 
CVD correlate with the number of comorbidities [28].
Meeting target goals in patients with MI or stroke
The best achievement was present for blood pressure. In 
patients with MI, about two-thirds had a blood pressure 
below 130/80  mmHg (Fig.  2a). In patients with stroke, 
over 90 % reached recommended values (Fig. 3a). Differ-
ences in achievement may be explained by higher target 
values for stroke patients (70–90  mmHg for diastolic; 
120–140 mmHg for systolic blood pressure). In German 
type 2 diabetes guidelines, target value for blood pres-
sure is 140/80 mmHg [34]. This objective was achieved in 
68.6 % of our study population without MVCs.
Studies investigating secondary prevention of MI or stroke 
in patients with type 2 diabetes are lacking. However, there 
are studies analyzing the prevalence of CVD risk factors in 
patients with diabetes, irrespective of previous MVC events 
[22, 24, 25]. Compared to results of the ESTHER-study, a 
German cohort study from Saarland (population-based 
data on primary care; patients with diabetes, n  =  1375), 
achievement of recommended blood pressure targets in 
the DPV study population is high. In the ESTHER-study, 
only 8.7 % reached a blood pressure below 130/80 mmHg 
[24]. Findings from the German DIAB-CORE project 
(pooled data from six population-based studies; patients 
with type 2 diabetes, n = 1287), reported in 36.4 % of the 
subjects a blood pressure below 140/90 mmHg [25]. In an 
analysis of the National Health and Nutrition Examination 
Table 2 Comparison of  sociodemographic and  clinical characteristics between  type 2 diabetes patients with  different 
MVCs
Data are medians (Q1;Q3) unless otherwise indicated
* p values adjusted for multiple comparisons by FDR
MI only (n = 15,015) Stroke only (n = 11,738) MI and stroke (n = 2572) p*
n n n
Men,  % 15,015 63.0 11,738 50.1 2572 60.6 <0.0001
Age (years) 15,015 72.4 (65.1;78.8) 11,738 74.8 (67.9;81.0) 2572 74.8 (68.5;80.4) <0.0001
Age at diagnosis (years) 15,015 60.9 (51.4;69.3) 11,738 63.9 (54.6;72.0) 2572 61.8 (52.0;70.0) <0.0001
Diabetes duration (years) 15,015 9.6 (3.9;16.2) 11,738 9.6 (4.2;15.2) 2572 11.0 (6.2;19.2) <0.0001
BMI (kg/m2) 13,887 29.2 (26.0;33.1) 9902 28.7 (25.5;32.7) 2255 29.1 (25.7;32.9) <0.0001
HbA1C (%) 13,795 6.9 (6.2;8.1) 10,889 7.0 (6.2;8.3) 2407 7.1 (6.3;8.3) <0.0001
Systolic BP (mmHg) 14,576 130.0 (120.0;140.0) 11,296 135.0 (120.0;149.0) 2496 130.0 (120.0;140.0) <0.0001
Diastolic BP (mmHg) 14,562 74.0 (70.0;80.0) 11,287 80.0 (70.0;80.0) 2496 75.0 (70.0;80.0) <0.0001
Total Chol (mg/dl) 12,750 166.0 (139.2;197.2) 8808 181.0 (150.0;216.0) 2087 169.0 (140.0;203.0) <0.0001
LDL-Chol (mg/dl) 12,086 94.0 (73.0;121.0) 8245 107.9 (82.0;138.0) 1997 96.0 (73.0;126.0) <0.0001
HDL-Chol (mg/dl) 12,176 41.0 (34.0;50.0) 8212 43.0 (35.0/52.0) 2001 41.0 (34.0;50.0) <0.0001
Physical inactivity,  % 5217 90.4 4869 94.5 1207 93.3 <0.0001
Smoking, yes,  % 12,049 10.0 9189 8.8 2210 9.2 0.0173
Cigarettes per day 1200 15 (10;20) 809 15 (10;20) 201 15 (10;20) 0.1579
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Survey (NHANES) from the USA, in the years 2007–2010 
(n = 1376), blood pressure of <130/80 mmHg was achieved 
in 51.1  % of the patients, and values <140/90  mmHg in 
72.0  % [22]. Results of the EUROASPIRE IV (European 
Action on Secondary and Primary Prevention by Interven-
tion to Reduce Events) study, including patients of 24 Euro-
pean countries, reported in 32 % of the patients with newly 
diagnosed diabetes and in 26 % of the patients with known 
diabetes a blood pressure <130/80 mmHg [35].
In guidelines for secondary prevention of MI/stroke, 
normoglycemia is recommended without a specific cut 
off value [13–15]. According to general national type 2 
diabetes guidelines, HbA1C should be between 6.5 and 
7.5  % depending on patients’ needs and preferences 
[34]. We therefore set a threshold of <7.5  %. An HbA1c 
<7.5  % was documented in approximately two-thirds of 
the patients with stroke (61.6  %), or MI (64.9  %). This 
is comparable to subjects without MVCs (60.1  %). A 
recently published study from Wales analyzed changes 
in HbA1C levels in patients with diabetes before and 
1 year after stroke [36]. The authors reported a significant 
improvement in HbA1C levels from 7.7 to 7.3 %. They also 
Fig. 2 Achievement of treatment goals in patients with type 2 diabetes and myocardial infarction MI. a Cardiovascular risk control values and 
lifestyle factors b medications
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compared the achievement of HbA1C levels ≤7.5  % in 
diabetes patients with and without stroke. One year after 
the incident stroke, an HbA1C ≤7.5 % was documented in 
62.5 % of patients who experienced stroke and in 65.3 % 
of the controls [36]. Our findings are also in line with 
results of the NHANES study. These authors reported an 
HbA1C of <7.0 % in 52.5 % of the patients, and an HbA1C 
of <8.0 % in 77.9 % [22].
In our study population, achievement of LDL targets 
was worst. Values below 100 mg/dl were present in only 
42.2 % of the patients with stroke (Fig. 3a), and in 56.2 % 
of the patients with MI (Fig. 2a). LDL <100 mg/dl is also 
recommended in type 2 diabetes without MVCs [34]. 
Even in these subjects, only 38.8 % met the goal. Hence, 
high values of LDL might be an overall problem in type 
2 diabetes. However, in a direct comparison with other 
Fig. 3 Achievement of treatment goals in patients with type 2 diabetes and stroke. a Cardiovascular risk control and lifestyle factors b medications
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studies from Germany, clinical characteristics of DPV-
patients are better. For example in the ESTHER-study, 
only in 13.3  % of the patients, LDL <100  mg/dl was 
reported [24]. In the DIAB-CORE study, only informa-
tion on the mean LDL was available. The mean LDL-value 
of 137 mg/dl is much higher compared to our study pop-
ulation (105 mg/dl in patients with MVCs, 115 mg/dl in 
patients without MVCs) [25]. In the US, 56.2 % achieved 
LDL <100 mg/dl [22]. The EUROASPIRE IV study indi-
cated in 56 % of the patients with newly diagnosed diabe-
tes and in 66 % with known diabetes LDL values <97 mg/
dl [35]. Overall, patients included in the current DPV 
study seem to have better control of CVD risk compared 
to subjects of other German cohorts [24, 25, 37]. Patients 
in DPV are mainly treated in specialized diabetes centers, 
whereas participants of the ESTHER study or the DIAB-
CORE project are predominantly treated by general 
practitioners [24, 25]. This could be one explanation for 
better treatment. Additionally, benchmarking with other 
centers participating in the DPV initiative might further 
encourage the diabetes team to improve clinical care in 
their patients [38].
Lifestyle factors
In the DPV database, the documentation of smok-
ing was missing in 19.8  % (n  =  2966) with MI, and in 
21.7  % (n  =  2549) with stroke. Most patients (>90  %) 
reported to be a non-smoker. This roughly correspond-
ents to the prevalence in the general population. Accord-
ing to the German census, smoking prevalence ranges 
from 22.0 % in the 60 to <65 year olds to 5.2 % in sub-
jects over 75  years of age [39]. The low smoking preva-
lence reported in diabetes subjects should be assessed 
positively, however, under-reporting cannot be com-
pletely excluded.
Physical activity is also recommended in the secondary 
prevention of MI and stroke. In the present analysis, 5 to 
10 % of patients with MI or stroke reported to be physi-
cally active (Figs. 2a, 3a). In the ESTHER-study, physical 
activity was reported in 43.6  % [24]. However, in DPV, 
only physical activity in guided sport-groups is docu-
mented by the diabetes team. This could be one explana-
tion for the lower percentage. Physical activity in guided 
sport-groups is important directly after the first episode 
after MI/stroke. Since we analyze the last treatment year 
of the patients, it is possible, that the MI/stroke already 
dates back several years. Hence, guided sport-groups are 
no longer required and it is possible that patients exercise 
privately. Furthermore, physical immobility due to stroke 
could be a limiting factor in physical activity. Moreo-
ver, in the DPV database, information on physical activ-
ity is available in only 34.7 % (MI) and 41.5 % (stroke) of 
patients.
Recommendations on BMI are present only in guide-
lines for MI. According to national guidelines [13], body 
weight should be reduced if the BMI is over 27  kg/m2. 
In our analysis, 32.2 % had a BMI <27 kg/m2. In patients 
without MVCs, the proportion is slightly lower (29.9 %). 
A study from Sweden demonstrated the importance 
of successful weight management in newly diagnosed 
patients with type 2 diabetes [40]. The authors stated 
that overweight and obese subjects had a substantially 
increased risk of incident atrial fibrillation compared to 
normal weight subjects. Even modest weight gain during 
the first 1.5  years after diabetes diagnosis seemed to be 
associated with increased atrial fibrillation risk [40].
Table 3 Gender differences in the attainment of guideline recommendations, separately for MI and stroke
* Data adjusted for age-groups (20–<65, 65–<75, >75 years of age)
MI only Stroke only
Men (n = 9455) Women (n = 5560) p* Men (n = 5883) Women (n = 5855) p*
HbA1C <7.5 %, % 65.8 64.1 0.0553 62.2 61.4 0.4082
Blood pressure <130/80 (mmHg), % 67.4 66.5 0.2679 – – –
Blood pressure 120/70–140/90 (mmHg), % – – – 90.0 89.5 0.1583
LDL-cholesterol <100 (mg/dl),  % 60.1 49.2 <0.0001 46.1 38.3 <0.0001
BMI <27 (kg/m2),  % 33.5 28.6 <0.0001 – –
Inhibitors of platelet aggregation, % 51.3 49.4 0.0137 32.7 30.5 0.0118
Statins, % 58.5 54.5 <0.0001 42.0 38.2 <0.0001
ACE inhibitors, % 51.3 46.9 <0.0001 42.2 40.3 0.0414
Beta blockers, % 59.7 59.0 0.4290 – – –
Any type of antihypertensives, % 65.9 63.8 0.0115 65.1 66.7 0.0684
Non-smoker, % 92.0 94.0 <0.0001 92.4 95.3 <0.0001
Physically active, % 9.5 8.5 0.2201 5.8 4.7 0.0887
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Medication
Except for antihypertensive drugs (MI: 65.1  %; stroke: 
65.8 %), concordance with recommendations is very low 
in our study population (Figs.  2b, 3b). Treatment goals 
are met more frequently in patients with MI compared 
to subjects with stroke. The use of IPA (31.7 %) is espe-
cially low in patients with stroke. As already mentioned, 
we analyzed the last year of treatment. It is therefore pos-
sible that recommendations were observed initially, but 
treatment was discontinued over time. In a large analysis 
of a German sickness fund (n = 30.028), initial prescrip-
tion prevalence after myocardial infarction and treatment 
after 5 years were evaluated [29]. Initial prescription was 
higher compared to our analysis. Beta blockers were 
prescribed in 82  % of the patients, statins in 73  %, and 
ACE inhibitors in 69 % [29]. However, 5 years after a MI, 
only few of the subjects were still treated according to 
recommendations with 36  % of the patients prescribed 
beta-blockers, 31  % ACE inhibitors, and in 17  % statins 
[29]. A very large study with over half a million subjects 
from the UK Biobank highlighted that medication was 
in many people not according to secondary prevention 
recommendations [26]. A study from the USA analyzed 
treatment in 364 subjects who survived coronary heart 
disease [41]. Best adherence to recommendations was 
present for lipid lowering drugs (60 %), followed by beta 
blockers (58  %) and ACE inhibitors (38  %) [41]. Other 
European countries, such as the Netherlands [27], and 
Denmark [42] have reported a low proportion of subjects 
meeting guideline-defined treatment goals. To improve 
secondary prevention of CVD, the introduction of the 
“polypill” (fixed-dose combination pill) is discussed [43]. 
The polypill concept was recently implemented in a num-
ber of European countries and in the USA [43].
Subgroup analysis
In almost all cases, treatment goals were met more often 
in men compared to women (Table 3). Some studies con-
firm our findings [28, 44, 45], while others do not [23, 24, 
46]. For example, the analysis of Xin Song and colleagues 
indicated in all categories of anthropometric measures 
of obesity a higher CVD mortality in men compared to 
women [46]. A suboptimal achievement of target values 
was also present in those patients treated with antihyper-
tensives or statins—except of blood pressure in patients 
with stroke. Only half of the statin-treated subjects 
with MI (49.8  %) and less than two-thirds with stroke 
(62.8 %) achieved LDL <100 mg/dl. In patients with MI 
treated with antihypertensives, only about two-thirds 
(66.6  %) achieved recommended blood pressure values 
of <130/80 mmHg. This gives rise to the assumption that 
medication is underdosed in clinical practice. Underdose 
in CVD medication was confirmed by other studies [47, 
48]. Steinberg et al. stated that less than half of the sub-
jects with acute coronary heart syndrome reached target 
values of LDL <100  mg/dl and that the recorded statin 
doses were lower than those with an evidence-based 
effect [48]. This was also reported by a study from the 
Euro Heart Survey on Diabetes and the heart [47]. The 
authors indicated that neither dosage of antihypertensive 
drugs nor dosages of statins were increased despite blood 
pressure and serum lipids exceeding recommended tar-
gets [47]. Although there are many studies indicating an 
improvement in survival and quality of life in patients 
who received medical treatment according to guidelines 
[21, 49, 50], a significant discrepancy between recom-
mendations and actual care is present. There are many 
potential reasons for this gap. Aside from a lack of knowl-
edge of current guidelines, physician inexperience, lack 
of physician time, or patients’ non-adherence, clinical 
reasons such as comorbidities or adverse effects of medi-
cations might also be present [18, 21, 51]. Furthermore, 
external constraints for example the type of health insur-
ance (private vs. statutory health insurances), access to 
medical care (including distance to the medical practice, 
or availability of specialists), or financial aspects may also 
be implicated [18, 21, 51]. Another reason could be a lack 
of resources available to implement secondary preven-
tion measures [21].
Strengths and limitations
The main strength of the current observational study 
is its large number of patients. Since we solely consider 
subjects from centers participating in the DPV initia-
tive, a selection bias cannot be completely excluded and 
the generalizability of our results might be therefore lim-
ited. Another shortcoming is that we could only assess 
the proportion of patients meeting treatment goals and 
not the reasons for non-adherence. A further limitation 
is that clinical characteristics and medical treatment were 
not completely documented in all patients with MI, or 
stroke. However, up to now, there seems to be no com-
parable study investigating adherence to current second-
ary prevention guidelines of MI, or stroke in the high-risk 
group of type 2 diabetes subjects. Despite these limita-
tions, analyses as the present one are urgently needed to 
reveal weaknesses in medical care providing an evidence 
basis for improvement.
Conclusion
This cross-sectional study indicates that medication and 
lifestyle changes for secondary prevention in subjects 
with type 2 diabetes who already experienced MI, or 
stroke are not in line with guideline recommendations. 
Overall, patients with stroke less frequently met treat-
ment goals compared to subjects with MI. Especially the 
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use of IPA was low. This analysis also confirms the need 
to improve secondary prevention of CVD risk factors. 
Aside from greater efforts by physicians to implement 
current guidelines, new strategies need to be developed 
to further increase patient motivation and compliance to 
hopefully result in sustainable behavior changes, includ-
ing increased physical activity and healthy food choices.
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